Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $96.00 | Outperform | Robert W. Baird |
| 4/11/2024 | $88.00 | Buy | CL King |
| 2/7/2024 | $87.00 | Neutral | BofA Securities |
| 12/21/2023 | $100.00 | Hold → Buy | Canaccord Genuity |
| 12/20/2022 | $73.00 → $72.00 | Buy → Hold | Canaccord Genuity |
| 2/25/2022 | $73.00 → $72.00 | Outperform | Raymond James |
| 2/25/2022 | $83.00 → $73.00 | Buy | Needham |
| 10/29/2021 | $68.00 → $74.00 | Equal-Weight | Wells Fargo |
9 analysts have expressed a variety of opinions on Merit Medical Systems (NASDAQ:MMSI) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 5 0 0 0 Last 30D 0 1 0 0 0 1M Ago 2 2 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 2 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $99.78, with a high estimate of $125.00 and a low estimate of $85.00. Witnessing
Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:MMSI) with a Outperform and maintains $100 price target.
Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:MMSI) with a Outperform and maintains $100 price target.
SOUTH JORDAN, Utah, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced positive six-month findings from the single-arm AVG cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The data were presented at the 51st annual VEITHsymposium during the Novel Technologies in Hemodialysis Access session. An AVG is a synthetic tube that is used for long-term access to blood vessels for patients undergoing hemodialysis. However, over time, the graft may become narrow or blocked, resulting in potentially life-threatening consequences. Merit's WRAPSODY Cell-Impermeable Endoprosthesis is designe
SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical's lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of cash on hand and borrowings under its long-term credit facility. "We are pleased to announce the completion of this important acquisition," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "We are excited to welcome the talented team from Cook Me
Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8%Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectivelyGAAP operating margin of 11.0%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.2%, compared to 17.4% in prior year periodGAAP EPS $0.48, up 8.0%, and non-GAAP EPS* $0.86, up 21.1%Generated free cash flow* $120 million over the first nine months of 2024, up 116% year-over-yearCompleted the acquisition of certain assets from EndoGastric Solutions, Inc., which included the EsophyX® Z+, a device intended for the treatment of chronic gastroesophageal reflux diseaseAnnounced positive 6-month findings
SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven
Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit
SOUTH JORDAN, Utah, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today outlined the ongoing succession planning process for its Chief Executive Officer (CEO). Pursuant to an Amended and Restated Employment Agreement, effective June 8, 2023, Merit founder, CEO, and President, Fred Lampropoulos, will continue to serve as Merit's CEO and President through December 31, 2025. To carry out its responsibility for CEO succession, the Merit Board of Directors appointed a special steering committee of independent directors led by Ann Millner, Ed.D., Lead Independent Director. The committee is deve
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00
CL King initiated coverage of Merit Medical with a rating of Buy and set a new price target of $88.00
BofA Securities initiated coverage of Merit Medical with a rating of Neutral and set a new price target of $87.00
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
10-Q - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical's lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of cash on hand and borrowings under its long-term credit facility. "We are pleased to announce the completion of this important acquisition," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "We are excited to welcome the talented team from Cook Me
Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8%Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectivelyGAAP operating margin of 11.0%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.2%, compared to 17.4% in prior year periodGAAP EPS $0.48, up 8.0%, and non-GAAP EPS* $0.86, up 21.1%Generated free cash flow* $120 million over the first nine months of 2024, up 116% year-over-yearCompleted the acquisition of certain assets from EndoGastric Solutions, Inc., which included the EsophyX® Z+, a device intended for the treatment of chronic gastroesophageal reflux diseaseAnnounced positive 6-month findings
SOUTH JORDAN, Utah, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2024, after the close of the stock market on Wednesday, October 30, 2024. Merit will hold its investor conference call on the same day (Wednesday, October 30, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide dec
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r